PsychonautWiki Archive

ΑMT

Revision as of 15:11, 20 March 2017 by >White (Text replacement - "{| |- | 17px''Main articles: Research chemicals § Toxicity and harm potential'' ''&'' ''Responsible use § Hallucinogens'' |}" to "{{further|Research chemicals#Toxicity and harm potential|Responsible use #Hallucinogens}}")

α-Methyltryptamine (abbreviated αMT; also known as AMT, aMT, and Indopan) is a synthetic tryptamine with entactogenic, stimulant and psychedelic effects.[1] It was originally developed as an antidepressant by workers at a Michigan pharmaceutical manufacturing company known as Upjohn in the 1960s.[2]

ΑMT
Chemical Nomenclature
Common names AMT, αMT, Indopan
Substitutive name α-Methyltryptamine, alpha-methyltryptamine
Systematic name 1-(1H-indol-3-yl)propan-2-amine
Class Membership
Psychoactive class Entactogen / Psychedelic
Chemical class Tryptamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



⇣ Oral
Dosage
Threshold 5 mg
Light 10 - 25 mg
Common 25 - 40 mg
Strong 40 - 60 mg
Heavy 60 - 80 mg
Duration
Total 13 - 15 hours
Onset 60 - 180 minutes
Peak 4 - 6 hours
After effects 1 - 5 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions
Alcohol
Caffeine
Cannabis
2C-T-x
2C-x
5-MeO-xxT
Amphetamines
Cocaine
DOx
DXM
MAOIs
MDMA
Mescaline
MXE
25x-NBOMe
PCP
SSRIs
Tramadol
Summary sheet: AMT

In the 1960s αMT was prescribed in 5 - 10 milligram doses as an antidepressant in the Soviet Union under the trade name Indopan.[3]

Erowid has received "a handful of unverifiable reports of hospitalization after high-dose (over 60 mg oral) αMT ingestion."[4] There were 22 deaths linked to AMT in England and Wales where the drug became popular as a legal high from 2012 until it was banned in early 2015.[5]. One widely reported fatality involved an 18 year old male who was believed to have taken just under a gram - a large overdose.[6] There is also an earlier reported death from AMT which was reported in February 2003 by the Miami-Dade County Medical Examiner Department, but it is unknown how much was taken.[7]

Chemistry

 
Generic structure of a tryptamine molecule

αMT, or α-Methyltryptamine is a synthetic indole alkaloid molecule of the tryptamine class. Tryptamines share a core structure comprised of a bicyclic indole heterocycle attached at R3 to an amino group via an ethyl side chain. AMT is substituted at the alpha carbon Rα of its tryptamine backbone with a methyl group. AMT is found in freebase form as a racemate of its (R-) and (S-) enantiomers.[8]

Pharmacology

Further information: Serotonergic psychedelic

αMT's psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist.

αMTalso acts as a releasing agent of serotonin, noradrenaline, and dopamine.[9][10] It also acts as a very weak, non-selective RIMA in-vitro[11] and in-vivo.[12], but this is unlikely to be very significant (if at all) with common doses.

However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

Subjective effects

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

The physical effects of this substance may be overly intense for those who are not already experienced with psychedelics.

  • Spontaneous tactile sensations - AMT's "body high" can be described as an intense and constant all-encompassing sensation. In comparison to other psychedelics, this sensation does not manifest itself in the form of a continuously shifting tingling sensation that travels up and down the body spontaneously; it is instead felt like an extended, unchanging activation of every nerve ending on the body that lasts throughout the entire duration of the trip. This continuous sensation is immensely pleasurable but can become overwhelmingly intense and almost a burden at higher levels.
  • Stimulation - Regarding its effects on the physical energy levels of the tripper, AMT is very stimulating, resulting in jaw clenching and a shakiness and unsteadiness of the hands. The stimulation encourages trippers to move around, run, dance, climb or engage in physical activities. In comparison, other more commonly used psychedelics such as psilocybin are sedating and relaxed.
  • Difficulty urinating - A slight difficulty urinating is occasionally present.
  • Headaches - Many people report headaches towards the end of the experience
  • Increased blood pressure
  • Increased heart rate
  • Increased perspiration
  • Nausea - Given the physical discomfort experienced on this substance, moderate to extreme nausea is almost consistently reported when consumed at any dosage. This either passes once the tripper has vomited or gradually fades by itself as the peak sets in.
  • Pupil dilation
  • Temperature regulation suppression

Cognitive effects

In comparison to more traditional psychedelics such as LSD, DMT and Psilocin, the AMT head space is described as not nearly as deep, insightful or profound.

The total sum of these cognitive components regardless of the setting generally includes:

Visual effects

The visual effects of AMT are mostly present only when large doses have been consumed and are proportionally mild in comparison to the intensity of its accompanying cognitive and physical effects when compared to substances such as LSD and psilocin.

Enhancements

Distortions

Geometry

The visual geometry that is present throughout this trip can be described as more similar in appearance to that of Psilocin, and 2C-E than LSD. At lower levels it can appear to be bland and simplistic in complexity but becomes equal regarding intricacy and depth to that of any of the classical psychedelics at higher dosages. It can be comprehensively described with its variations as intricate in complexity (at heavy dosages), abstract in form, organic in feel, structured in organization, brightly lit, multicoloured in scheme, glossy in shading, equal in soft and sharp edges, small in size, fast in speed, smooth in motion, equal in round and angular corners, non-immersive in depth, and consistent in intensity. At higher dosages, the visual geometry is significantly more likely to result in states of Level 8B geometry over Level 8A.

Hallucinatory states

  • Transformations
  • Internal hallucinations (autonomous entities; settings, sceneries, and landscapes; alterations in perspective and scenarios and plots) - This particular effect is uncommon during the first half of the trip but capable of manifesting itself towards the end of the experience, particularly if sleep deprivation starts to take its toll due to the abnormally long duration. The internal hallucinations are more common within dark environments and can be comprehensively described through their variations as lucid in believability, fixed in style, new experiences in content, autonomous in controllability, geometry-based in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.

Auditory effects

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Toxicity and harm potential

Further information: Research chemicals § Toxicity and harm potential, and Responsible use § Hallucinogens

As a powerful monoamine reuptake inhibitor, αMT can be dangerous when taken in excessive doses or when combined with substances such as MAOIs, RIMAs, stimulants and any substance which act as a releasing agent or reuptake inhibitor of serotonin and dopamine. There is one reported death from AMT, but it is not known how much of the substance was taken.[7] Erowid states that they have received "a handful of unverifiable reports of hospitalization after high-dose (over 60 mg oral) AMT ingestion."[4]

The toxicity and long-term health effects of recreational αMT use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because AMT is a research chemical with very little history of human usage. Anecdotal evidence from people who have tried AMT within the psychedelic community suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is worth noting that αMT's analogue αET has been shown to produce long-lasting serotonergic neurotoxicity at very high doses.[13] It is possible that AMT could cause the same neurotoxicity at high dosages or with repeated long-term use.

It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

AMT is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.

Tolerance to the effects of αMT are built almost immediately after ingestion. After that, it takes about Time to half tolerance::1 week for the tolerance to be reduced to half and Time to zero tolerance::2 weeks to be back at baseline (in the absence of further consumption). AMT presents cross-tolerance with [[Cross-tolerance::all psychedelics]], meaning that after the consumption of αMT all psychedelics will have a reduced effect.

Dangerous interactions

Deaths from αMT are rare[4][7] but, as a powerful monoamine reuptake inhibitor (MRI), injury could occur when excessive doses are taken or when it is taken with substances such as MAOIs, RIMAs, stimulants and any substance which act as a releasing agent or reuptake inhibitor of neurotransmitters such as serotonin and dopamine.[14]

  • Australia: Sale and possession of AMT is illegal.
  • Germany: Sale and possession of AMT is illegal.
  • Greece: Sale and possession of AMT is illegal.
  • Japan: Sale and possession of AMT is illegal.
  • Russia: Sale and possession of AMT is illegal.
  • Sweden: Sale and possession of AMT is illegal.[15]
  • USA: AMT is a Schedule I drug.[16]
  • United Kingdom: AMT is a Class A substance and the sale and possession are illegal. See "the Misuse of substances Act 1971 (Amendment) (No. 2) Order 2014"[17]
  • Canada: Canada has no mention of this substance in the Controlled substances and Substances Act.[18]
  • Latvia: AMT is a Schedule I drug.[19]

See also

References

  1. ↑ Erowid Online Books : TIHKAL - #48 a-MT | http://www.erowid.org/library/books_online/tihkal/tihkal48.shtml
  2. ↑ US Patent 3296072 - Method of Treating Mental Depression
  3. ↑ AMT's TiHKAL entry by Alexander Shulgin (IsomerDesigns) https://isomerdesign.com/PiHKAL/read.php?domain=tk&id=48
  4. ↑ 4.0 4.1 4.2 AMT (Alphamethyltryptamine, IT-290) Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/amt/amt_death.shtml
  5. ↑ Deaths Related to Drug Poisoning, England and Wales, 2016 release (table 8) | https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/deathsrelatedtodrugpoisoningenglandandwalesreferencetable
  6. ↑ Call to ban legal high drug AMT, The Telegraph, 10th June 2014 | http://www.telegraph.co.uk/news/uknews/law-and-order/10890567/Call-to-ban-legal-high-drug-AMT.html
  7. ↑ 7.0 7.1 7.2 Boland DM, Andollo W, Hime GW, Hearn WL. “Fatality due to acute alpha-methyltryptamine intoxication.” J Anal Toxicol. 2005 Jul-Aug;29(5):394-7. | https://www.erowid.org/references/refs_view.php?ID=6603 Cite error: Invalid <ref> tag; name "amt2" defined multiple times with different content
  8. ↑ http://isomerdesign.com/PiHKAL/read.php?id=48
  9. ↑ The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain | http://linkinghub.elsevier.com/retrieve/pii/S0014-2999(06)01381-1
  10. ↑ In vitro screening of psychoactive drugs by [(35)S]GTPgammaS binding in rat brain membranes | https://www.jstage.jst.go.jp/article/bpb/30/12/30_12_2328/_article
  11. ↑ Studies of Monoamine Oxidase and Semicarbazide-Sensitive Amine Oxidase II. Inhibition by α-Methylated Substrate-Analogue Monoamines, α-Methyltryptamine, α-Methylbenzylamine and Two Enantiomers of α-Methylbenzylamine | https://www.jstage.jst.go.jp/article/jphs1951/41/2/41_2_191/_article
  12. ↑ THE EFFECT OF THREE TRYPTAMINE DERIVATIVES ON SEROTONIN METABOLISM IN VITRO AND IN VIVO | http://jpet.aspetjournals.org/content/127/2/110.short
  13. ↑ Reduction in brain serotonin markers by α-ethyltryptamine (Monase) (ScienceDirect) | http://www.sciencedirect.com/science/article/pii/001429999190686K
  14. ↑ Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity | http://bja.oxfordjournals.org/content/95/4/434
  15. ↑ Svensk författningssamling Förordning om ändring i förordningen (1999:58) om förbud mot vissa hälsofarliga varor | http://www.notisum.se/rnp/sls/sfs/20050026.pdf
  16. ↑ Drug Enforcement Administration | http://webcache.googleusercontent.com/search?q=cache:http://www.deadiversion.usdoj.gov/drug_chem_info/amt.pdf
  17. ↑ the Misuse of substances Act 1971 (Amendment) (No. 2) Order 2014 | http://www.legislation.gov.uk/uksi/2014/3271/article/4/made
  18. ↑ CSDA | http://isomerdesign.com/Cdsa/schedule.php?structure=C
  19. ↑ Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (Triptamīni) | http://likumi.lv/doc.php?id=121086


Retrieved from "http://psy.st/w/index.php?title=ΑMT&oldid=82713"